Novo Nordisk is increasing its footprint in the obesity sphere. The Danish pharma firm’s parent company, Novo Holdings, is acquiring contract drug manufacturer Catalent in a deal worth up to $16.5 billion.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,